Learning Center

Learning Center

December 2024 - Quality Bone Densitometry: Performance, Interpretation, and Clinical Application for Clinicians

Includes Multiple Live Events. The next is on 12/07/2024 at 10:00 AM (EST)

  • Register
    • Non-Member - $800
    • Full Member - $500
    • MOC Only - $800
    • Community Member - $800
    • Professional Member - $800

Course Date

December 7 & 8, 2024.

Course Description

The core elements of this course serve to educate healthcare providers about bone densitometry and osteoporosis and to apply standard practices to assure quality performance and interpretation of bone densitometry studies. The course is offered in two parts. The first day sets the standard to perform Quality DXA interpretation. Day 2 focuses on the clinical assessment, prevention, treatment and management of osteoporosis and the essential role that high-quality DXA plays in treatment initiation decisions and monitoring of osteoporotic patients. Individuals may register for either part of the course separately or as a combined program.

Target Audience

The course is most appropriate for those involved in the performance and interpretation of DXA scans and those managing patients with osteoporosis. It is open to MDs, PhDs, DOs, Nurse Practitioners, and Physician Assistants. Technologists may attend if they have previously taken the ISCD/IOF Osteoporosis Essentials for Technologists Course.

Learning Objectives

After attending the course, participants should be better prepared to:

  • Describe appropriate clinical evaluation of patients at risk for fragility fracture.
  • Summarize the value and importance of quality bone densitometry for the diagnosis of osteoporosis, assessment of fracture risk, and monitoring of BMD. 
  • Recognize errors in DXA analysis and reporting. 
  • Explain new and emerging guidelines that provide evidence-based information regarding skeletal health. 
  • Describe the use of current and new pharmacologic therapies for the management and treatment of osteoporosis, including adverse effects.

Method of Participation

This activity will be offered live streamed via Zoom, allowing the learner to watch and ask questions in a live format on December 7 & 8, 2024. Learners will be asked to complete a post-course survey to indicate what they will change in their practice as a result of this activity.



Cancellation Policy

Attendee Cancellation Policy All changes in registration must be made in writing to education@iscd.org. Cancellations received 30 days prior to the start of the program are eligible for a full refund minus a $50 administrative fee. Cancellations received less than 30 days prior to the start of the course will not be refunded.

Course Changes or Cancellations ISCD reserves the right to cancel the program, change dates and/or meeting location. If a program is canceled, all program fees will be refunded automatically unless the registered participant elects to transfer to another program. Participants will be notified of any changes within 21 days of the course start date.

ACCME Joint Accreditation Statement:

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and ISCD. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.


AMA PRA Category 1 Credit(s)™

Amedco LLC designates this live activity for a maximum of 13.00 AMA PRA Category 1 CreditsTM

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Deadline to Claim Credit:

Participants will have 90 days from the activity end date to complete the activity survey and claim continuing education credit.

 Schedule - December 7th, 2024 - All times Eastern Standard Time (NYC/USA)


 Schedule - December 8th, 2024 - All times Eastern Standard Time (NYC/USA)


Dr Neil Binkley MD, CCD


University of Wisconsin Madison

Dr. Neil Binkley earned his medical degree from the University of Wisconsin and subsequently trained in Internal Medicine at the Marshfield Clinic. After several years in private practice, he returned to the University of Wisconsin and completed a Geriatrics fellowship. He is a Professor in the Divisions of Geriatrics and Endocrinology at the University of Wisconsin School of Medicine and Public Health. He is also Director of the UW Osteoporosis Clinical Research Program and Associate Director of the UW Institute on Aging. He is past President of the International Society for Clinical Densitometry, Associate Editor of Osteoporosis International and a member of the International Osteoporosis Foundation Committee of Scientific Advisors. His current research involves improvement in 25(OH)D measurement, evaluation of approaches to optimize assessment of vitamin D status, evaluation of functional assessment in older adults and the importance of sarcopenia in fracture risk. Dr. Binkley has published over 300 papers, served on expert committees and panels for AACE, ASBMR, IOF and ISCD.

E. Michael Lewiecki, MD, FACP, FACE, CCD


New Mexico Clinical Research & Osteoporosis Center, Inc.

E. Michael Lewiecki, MD, CCD, FACP, FACE, FASBMR, is Director of New Mexico Clinical Research & Osteoporosis Center and Director of Bone Health TeleECHO at University of New Mexico Health Sciences Center in Albuquerque, NM. His is a consultant in osteoporosis and metabolic bone disease, supervisor and interpreter of bone density studies, and an educator with a special interest in the evaluation and treatment of osteoporosis and metabolic bone diseases. He has been principal investigator for many osteoporosis clinical trials and is author of over 300 publications in peer-reviewed medical journals, as well as books, book chapters, and online publications on osteoporosis. Dr. Lewiecki is past-president of the International Society for Clinical Densitometry (ISCD) and current president of the Osteoporosis Foundation of New Mexico (OFNM). He is an editor for Osteoporosis International, and is on the editorial boards of the Journal of Bone and Mineral Research and the Journal of Clinical Densitometry. He has received national and international awards that include the 2021 “Dr. John P. Bilezikian ISCD Global Leadership Award” and the 2021 “Lawrence G. Raisz Memorial Lecture Award” with the Bone Health & Osteoporosis Foundation. Dr. Lewiecki is the program director of the annual Santa Fe Bone Symposium, the flagship activity of the OFNM.

Gillian Wooldridge, DO, CCD

Gillian Wooldridge is a primary care sports medicine physician in Houston, Texas. She completed her undergraduate studies in Kinesiology-Sports Medicine at Rice University in 2009. She received her medical degree from the Texas College of Osteopathic Medicine in 2014, where she was the inaugural recipient of the Sports Medicine Achievement Award. Dr Wooldridge completed her family medicine residency in 2017 and sports medicine fellowship in 2018, with Houston Methodist and Houston Methodist Willowbrook Hospitals respectively. 

She currently works for Houston Methodist Orthopedics and Sports Medicine in the Texas Medical Center. She serves as a team physician for Rice University Athletics and volunteers with several organizations in the community including the Chevron Houston Marathon, IronMan Texas and the Houston Livestock Show and Rodeo. Dr Wooldridge is a member of the board of directors for the American Osteopathic Academy of Sports Medicine and is actively involved in the American Medical Society of Sports Medicine as an item writer for the sports medicine in-training exam. 

She is a certified clinical densitometrist and works on the Osteoporosis Essentials Course Committee and serves as a co-director of the Bone Health Initiative in the Houston Methodist Orthopedics and Sports Medicine department. She holds a core clinical faculty position with the Texas A&M College of Medicine Engineering & Medicine program and a clinical faculty position the Tillman Fertitta Family College of Medicine. 


Statement of Independence

The ISCD maintains a policy on the use of commercial support, which ensures that all educational activities sponsored by the ISCD provide in-depth presentations that are fair, balanced, independent, and scientifically rigorous. ISCD requires faculty, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ISCD for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Individual disclosures are included in the course material. No Commercial Support has been provided for this activity


The information and suggestions presented at the courses, seminars and other programs sponsored by ISCD and other collaborating societies are subject to change and therefore should serve only as a foundation for further investigation and study. Any forms presented at our seminars or programs are samples only and are not necessarily authoritative. All information, procedures, and forms contained or used in such seminars or programs should serve only as a guide for use in specific situations.

Disclosure of Unlabeled Use

This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. ISCD does not recommend the use of any agent outside of the labeled indications. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for a discussion of approved indications, contraindications, and warnings.

Privacy & Confidentiality Statement

The ISCD will record the learner’s personal information as provided on evaluations to allow for the issuance and tracking of CME/CE certificates. The ISCD may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its educational program. No individual performance data or any other personal information collected for evaluations will be shared with third parties

Attendance Cancellation Policy

All changes in registration must be made in writing to education@iscd.org. Cancellations received 30 days prior to the start of the program are eligible for a full refund minus a $50 administrative fee. Cancellations received less than 30 days prior to the start of the course will not be refunded.

Course Changes or Cancellations

ISCD reserves the right to cancel the program, change dates, how the course is taught, and/or meeting location. If a program is canceled, all program fees will be refunded unless the registered participant elects to transfer to another program. Participants will be notified of any changes within 21 days of the course start date.

This content will not be available until 11/07/2024 at 9:00 AM (EST)